Heat shock protein 90 overexpression independently predicts inferior disease-free survival with differential expression of the α and β isoforms in gastrointestinal stromal tumors

Clinical Cancer Research

Volumn 14, Issue 23, 2008, Pages 7822-7831

  Li, Chien Feng ^a   Huang, Wen Wei ^d   Wu, Jing Mei ^e   Yu, Shih Chen ^e   Hu, Tsung Hui ^e   Uen, Yih Huei ^b   Tian, Yu Fang ^b   Lin, Ching Nan ^a   Lu, David ^c   Fang, Fu Min ^e   Huang, Hsuan Ying ^e  

^a Chi Mei Foundation Hospital   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

^c BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^d Buddhist Dalin Tzuchi Hospital   (Taiwan)

^e CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 ALPHA; HEAT SHOCK PROTEIN 90 BETA; ISOPROTEIN; KI 67 ANTIGEN; MESSENGER RNA; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; TUMOR MARKER;

ADULT; AGED; AGING; ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE OVEREXPRESSION; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; WESTERN BLOTTING; BIOSYNTHESIS; GENETICS; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; DISEASE-FREE SURVIVAL; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; PROTEIN ISOFORMS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 59449087254     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1369     Document Type: Article

References (43)

1. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002;33:459-65.
2. Heinrich MC,Rubin BP,Longley BJ,Fletcher JA. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 2002;33:484-95.
3. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004; 22:3813-25.
4. Hornick JL, Fletcher CD. The role of KIT in the management of patients with gastrointestinal stromal tumors. Hum Pathol 2007;38:679-87.
5. Huang HY, Huang WW, Lin CN, et al. Immunohisto- chemical expression of p16INK4A, Ki-67, and Mcm2 proteins in gastrointestinal stromal tumors: prognostic implications and correlations with risk stratification of NIH consensus criteria. Ann Surg Oncol 2006;13: 1633 -44.
6. Martin J, Poveda A, Llombart-Bosch A, et al. Deletions affecting codons 557 -558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS).J Clin Oncol2005;23:6190-8.
7. Nilsson B, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden. Cancer 2005;103:821 -9.
8. Antonescu CR, Sommer G, Sarran L, et al. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 2003;9:3329-37.
9. Lasota J, Dansonka-Mieszkowska A, StachuraT, et al. Gastrointestinal stromal tumors with internal tandem duplications in 3' end of KIT juxtamembrane domain occur predominantly in stomach and generally seem to have a favorable course. Mod Pathol 2003;16:1257 -64.
10. Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology 2008;53:245 -66.
11. Miettinen M, Makhlouf H, Sobin LH, LasotaJ. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906cases before imatinib with long-term follow-up. Am J Surg Pathol 2006; 30:477 -89.
12. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005;29:52 -68.
13. Fletcher JA, Rubin BP. KIT mutationsin GIST. Curr Opin Genet Dev 2007;17:3-7.
14. Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006;24: 4764-74.
15. Joensuu H. Second line therapies for the treatment of gastrointestinal stromal tumor. Curr Opin Oncol 2007;19:353 -8.
16. Antonescu CR, Besmer P, GuoT, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005;11:4182-90.
17. Debiec-Rychter M, CoolsJ, Dumez H, et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroen-terology 2005;128:270-9.
18. Sreedhar AS, Kalmar E, Csermely P, Shen YF. Hsp90 isoforms: functions, expression and clinical importance. FEBS Lett 2004;562:11 -5.
19. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005;5:761 -72.
20. Neckers L, Ivy SP. Heat shock protein 90. Curr Opin Oncol 2003;15:419 -24.
21. Xu W, Neckers L. Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells. Clin Cancer Res 2007;13:1625 -9.
22. Bauer S, Yu LK, Demetri GD, Fletcher JA. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res 2006;66: 9153-61.
23. Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 2005;10: 86-103.
24. ChangYS, Lo CW, Sun FC, Chang MD, Lai YK. Differential expression of Hsp90 isoforms in geldanamycin-treated 9L cells. Biochem Biophys Res Commun 2006;344:37-44.
25. Huang HY, Li CF, Huang WW, et al. A modification of NIH consensus criteria to better distinguish the highly lethal subset of primary localized gastrointestinal stromal tumors: a subdivision of the original high- risk group on the basis of outcome. Surgery 2007;141: 748-56.
26. Andersson J, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors with KITexon 11 deletions are associated with poor prognosis. Gastroenterology 2006;130:1573 -81.
27. Corless CL, McGreevey L, Haley A, Town A, Heinrich MC. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 2002;160:1567 -72.
28. Bauer S, Duensing A, Demetri GD, Fletcher JA. KIT oncogenic signaling mechanisms in imatinib- resistant gastrointestinal stromal tumor: PI3-kinase/ AKT is a crucial survival pathway. Oncogene 2007;26: 7560-8.
29. Dematteo RP, Gold JS, Saran L, et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 2008;112:608-15.
30. Singer S, Rubin BP, Lux ML, et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 2002;20:3898-905.
31. Emory TS, Sobin LH, Lukes L, Lee DH, O'Leary TJ. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol 1999;23:82-7.
32. Basso AD, Solit DB, Munster PN, Rosen N. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 2002;21:1159-66.
33. PrinceT, Sun L, Matts RL. Cdk2: a genuine protein kinase client of Hsp90 and Cdc37. Biochemistry 2005;44:15287 -95.
34. Srethapakdi M, Liu F,Tavorath R, Rosen N. Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest. Cancer Res 2000;60:3940-6.
35. Antonescu CR,Viale A, Sarran L, et al. Gene expression in gastrointestinal stromal tumorsis distinguished by KIT genotype and anatomic site. Clin Cancer Res 2004;10:3282 -90.
36. Subramanian S,West RB, Corless CL, et al. Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles. Oncogene 2004;23:7780-90.
37. Lasota J, Corless CL, Heinrich MC, et al. Clinico- pathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases. Mod Pathol 2008;21:476-84.
38. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-9.
39. Fumo G, Akin C, Metcalfe DD, Neckers L. 17-Allyla-mino-17- demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. Blood 2004;103:1078-84.
40. Nakatani H, Kobayashi M, Jin T, et al. STI571 (Glivec) inhibits the interaction between c-KIT and heat shock protein 90 of the gastrointestinal stromal tumor cell line, GIST-T1. Cancer Sci 2005;96:116 -9.
41. Xu A, Tian T, Hao J, et al. Elevation of serum Hsp90a correlated with the clinical stage of non-small cell lung cancer. J Cancer Mol 2007;3:107 -12.
42. Eustace BK, Sakurai T, Stewart JK, et al. Functional proteomic screens reveal an essential extra-cellular role for hsp90a in cancer cell invasiveness. Nat Cell Biol 2004;6:507 -14.
43. Yang Y, Rao R, Shen J, et al. Role of acetylation and extracellular location of heat shock protein 90αin tumor cell invasion. Cancer Res 2008;68: 4833 -42.